After coronary stent placement, can the patient continue bupropion (Wellbutrin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Wellbutrin (Bupropion) Be Continued After Coronary Stent Placement?

Yes, Wellbutrin can generally be continued after coronary stent placement, but requires careful blood pressure monitoring due to its hypertensive effects, particularly in the early post-stent period when patients are on dual antiplatelet therapy.

Key Cardiovascular Considerations

Blood Pressure Monitoring is Essential

The FDA label for Wellbutrin explicitly warns that treatment can result in elevated blood pressure and hypertension 1. Blood pressure must be assessed before continuing treatment and monitored periodically throughout therapy. This is particularly critical post-stent because:

  • Post-PCI guidelines mandate aggressive blood pressure control as part of secondary prevention 2
  • Hypertension increases cardiovascular risk in patients with coronary artery disease
  • Bupropion caused treatment-emergent hypertension in 2% of patients in clinical trials, with mean systolic BP increases of 1.3 mmHg 1

Evidence in Cardiac Populations

Research specifically examining bupropion in cardiac patients is reassuring:

  • In 36 depressed patients with preexisting heart disease (left ventricular impairment, ventricular arrhythmias, or conduction disease), bupropion at mean doses of 442 mg/day did not cause significant conduction complications, did not exacerbate ventricular arrhythmias, and had low rates of orthostatic hypotension 3
  • However, treatment was discontinued in 14% due to adverse effects, including exacerbation of baseline hypertension in 2 patients 3
  • In 10 depressed patients with congestive heart failure, bupropion did not adversely affect ejection fraction or other indices of left ventricular function 4

The FDA label specifically notes: "There are no controlled studies assessing the safety of bupropion in patients with a recent history of myocardial infarction or unstable cardiac disease" 1. This is the critical caveat—your patient with a recent stent falls into this category.

Clinical Decision Algorithm

Continue Bupropion If:

  1. Blood pressure is well-controlled (target <130/80 mmHg per secondary prevention guidelines 2)
  2. Patient is clinically stable post-stent (no ongoing ischemia, heart failure, or arrhythmias)
  3. Depression is moderate-to-severe and bupropion has been effective
  4. Patient is on appropriate post-stent medications (aspirin + P2Y12 inhibitor for at least 6-12 months per stent type) 5, 6, 7

Monitor Closely:

  • Blood pressure at every visit during the first 3 months post-stent
  • Weekly BP checks for the first month if continuing bupropion
  • Symptoms of chest pain, palpitations, or worsening angina

Consider Discontinuation or Alternative If:

  1. Baseline hypertension is poorly controlled (BP >140/90 mmHg)
  2. Patient develops new or worsening hypertension on bupropion
  3. Stent was placed for acute coronary syndrome within the last 6 weeks
  4. Patient has unstable cardiac disease or recent myocardial infarction

Post-Stent Medication Context

Your patient should be on comprehensive secondary prevention therapy 2, 8:

  • Dual antiplatelet therapy: Aspirin 75-162 mg daily indefinitely PLUS clopidogrel 75 mg daily for at least 12 months (drug-eluting stent) or 1 month minimum (bare metal stent) 5, 6
  • Beta-blocker: Especially if post-MI or reduced ejection fraction 2, 8
  • ACE inhibitor or ARB: If hypertension, diabetes, or LVEF <40% 2, 8
  • High-intensity statin: Target LDL <70 mg/dL 2, 8

The combination of bupropion with beta-blockers requires no dose adjustment and poses no specific interaction concerns. However, the cumulative effect on blood pressure from multiple medications must be monitored.

Common Pitfalls to Avoid

  1. Don't assume bupropion is contraindicated—it's not, but it requires monitoring
  2. Don't ignore blood pressure trends—even small increases matter in post-stent patients
  3. Don't abruptly discontinue bupropion—taper from 300 mg to 150 mg daily before stopping 1
  4. Don't forget that untreated depression worsens cardiac outcomes—depression is an independent risk factor for adverse events post-MI

Bottom Line

Continue Wellbutrin with vigilant blood pressure monitoring. The cardiovascular safety profile in cardiac patients is acceptable 3, 4, but the lack of data in acute post-stent patients 1 mandates close surveillance. If blood pressure becomes difficult to control or the patient develops cardiac symptoms, consider switching to an SSRI with neutral cardiovascular effects (e.g., sertraline, which has been studied extensively in post-MI populations).

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.